Return To Phacilitate
Register Today Exhibit With Us
SEARCH
Loading

This agenda is still in development. All sessions and timings are subject to regular change at this time. 

Search Filters
  • Date
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
  1. Fireside Chat: Reimagining allogeneic cell therapy: What success will look like in 2030
    Theatre 4
  2. Fireside Chat Rethinking the solid tumour landscape: Reassessing the opportunities and challenges in solid tumours
    Theatre 1 (Zafir)
  3. Spotlight
    Theatre 3
  4. Spotlight: Engineering the allogeneic edge: safety, efficacy & scalability breakthroughs
    Theatre 4
  5. Spotlight
    Theatre 1 (Zafir)
  6. Spotlight/Fireside Chat
    Theatre 3
  7. Panel: Winning the allogeneic race: Commercial viability in a crowded modality landscape
    Theatre 4
  8. Panel Overcoming the tumour microenvironment: Which strategies hold the greatest promise for solid tumours?
    Theatre 1 (Zafir)
  9. Panel discussion
    Theatre 3
  10. Panel: Accelerated approval in 2026: A necessary tool or a commercial liability?
    Theatre 4
  11. Panel: Where do cell and gene therapies fit in the future cancer treatment landscape?
    Theatre 4
  12. Spotlight: CAR-T manufacturing ' Technologies that unlock real scale
    Theatre 4
  13. Spotlight
    Theatre 1 (Zafir)
  14. Spotlight: Leveraging Prior Knowledge to Accelerate the Development of Multiple Liver-Directed Prime Editors
    Theatre 1 (Zafir)
  15. Spotlight/Fireside Chat
    Theatre 3
  16. Spotlight: Beyond the Membrane: Mechanistic insights into differential transduction by AAV capsids
    Theatre 3
  17. CDMO startey for the long term
  18. Spotlight: CART-T supply chain: Precision logistics for high-volume delivery
    Theatre 4
  19. Spotlight
    Theatre 1 (Zafir)
  20. Spotlight
    Theatre 1 (Zafir)
  21. Spotlight/Fireside Chat
    Theatre 3
  22. Spotlight/Fireside Chat
    Theatre 3
  23. Panel: Designing the end-to-end CAR-T Ecosystem: What it takes to treat the majority of patients
    Theatre 4
  24. Panel: Building a scalable early-development strategy: Selecting platforms and tools that enable rapid clinical proof of concept
    Theatre 1 (Zafir)
  25. Panel: Integrating new approach methodologies into early development: Where do NAMs deliver the greatest value?
    Theatre 1 (Zafir)
  26. Panel discussion: What is the data telling us about the clinical pathway to safe and efficacious in vivo gene therapy products?
    Theatre 3
  27. Panel discussion
    Theatre 3
  28. Spotlight: Engineering precision in vivo delivery with SHREAD adenoviral VLPs
    Theatre 3
  29. Spotlight/Fireside Chat
    Theatre 3
  30. Spotlight: Cellular nanoparticles for drug and gene delivery
    Theatre 3
  31. Panel discussion
    Theatre 3
  32. Presentation 1
  33. Presentation 19
  34. Regulator Drop In
  35. How do you plan and execute successful overseas IIT in the APAC and Australian regions?
  36. Presentation 2
  37. Presentation 20
  38. Spotlight/Fireside Chat
    Theatre 3
  39. Presentation 3
  40. Presentation 21
  41. Panel discussion
    Theatre 3
  42. Presentation 4
  43. Presentation 22
  44. Presentation 5
  45. Presentation 23
  46. Presentation 6
  47. Presentation 24
  48. TBC
    Indigo BCFG
  49. Fireside Chat: Autoimmune CGT development and safety pathway ' What success actually requires
    Theatre 4
  50. Spotlight: Cell therapy manufacturing re-engineered: Unlocking global access & scale out economics
    Theatre 4
  51. Spotlight
    Theatre 1 (Zafir)
  52. Fireside Chat
    Theatre 3
  53. Spotlight
    Theatre 3
  54. Presentation 7
  55. Presentation 25
  56. Meet the CRO
  57. Presentation 8
  58. Presentation 26
  59. Spotlgiht: Reserved
    Theatre 4
  60. Fireside Chat: Reserved
    Theatre 4
  61. Spotlight
    Theatre 1 (Zafir)
  62. Spotlight
    Theatre 3
  63. Spotlight
    Theatre 3
  64. Presentation 9
  65. Presentation 27
  66. Panel: Winning in autoimmune disease - Where CGTs can actually compete?
    Theatre 4
  67. Panel: Cracking the COGs challenge: What must change to make CGTs truly scalable?
    Theatre 4
  68. Panel: The benchtop bottleneck: Solving the scalable processing shortage
    Theatre 1 (Zafir)
  69. Panel discussion
    Theatre 3
  70. Panel discussion
    Theatre 3
  71. Presentation 10
  72. Presentation 28
  73. Presentation 11
  74. Presentation 29
  75. Presentation 12
  76. Presentation 30
  77. Roundtable: Responsibile use of AI manufacturing
  78. Roundtable: Cracking the EU Code: Turning regulatory & supply complexities into a smooth process
  79. Roundtable: Title tbc
  80. Roundtable: Can your workforce deliver the therapy? Measuring capability for advanced therapies
  81. Roundtable: Bringing early-phase trials back to the US
  82. AI Workshop
  83. How to reduce the current fragility of cell & gene therapy raw materials supply chains?
  84. Spotlight: Mastering the CGT supply chain: Starting materials, shelf life & the final mile
    Theatre 4
  85. Fireside Chat: Defining 'phase-appropriate' development: How much is enough to reach the clinic
    Theatre 1 (Zafir)
  86. Fireside Chat: Designing early clinical trials that generate meaningful proof of concept
    Theatre 1 (Zafir)
  87. Spotlight
    Theatre 3
  88. Spotlight: Designing analytical comparability assessments for process and manufacturing changes
    Theatre 3
  89. Presentation 13
  90. Presentation 31
  91. Presentation 14
  92. Presentation 32
  93. Spotlight: Automating the last mile: Tools that make point-of-care delivery scalable
    Theatre 4
  94. Spotlight
    Theatre 1 (Zafir)
  95. Spotlight
    Theatre 1 (Zafir)
  96. Spotlight/Fireside Chat
    Theatre 3
  97. Spotlight/Fireside Chat
    Theatre 3
  98. Presentation 15
  99. Presentation 33
  100. Panel: Supply chain as a commercial strategy: The new determinant of market access
    Theatre 4
  101. Panel: Beyond IND: Balancing early CMC decisions with long-term commercial success
    Theatre 1 (Zafir)
  102. Panel: Executing early clinical trials efficiently. Overcoming operational barriers to proof of concept
    Theatre 1 (Zafir)
  103. Panel discussion
    Theatre 3
  104. Panel discussion
    Theatre 3
  105. Presentation 16
  106. Presentation 34
  107. Presentation 17
  108. Presentation 35
  109. Presentation 18
  110. Presentation 36
  111. Chair's introduction
    Theatre 1 (Zafir)
  112. Top 5 trends for 2027
    Theatre 1 (Zafir)
  113. Keynote industry perspective
    Theatre 1 (Zafir)
  114. Keynote Discussion: Integrating product delivery and market access for the next generation of cell & gene therapies
    Theatre 1 (Zafir)
  115. Keynote Regulatory Roundtable - perspectives on key areas of importance to the cell & gene therapy industry
    Theatre 1 (Zafir)
  116. Pharma Roundtable: Assessing R&D, commercial and business development strategies and priorities spanning the cell & gene therapy field
    Theatre 1 (Zafir)
  117. Roundtable discussion - the Global Picture
    Theatre 1 (Zafir)
  118. Fireside Chat: How to manufacture your biologics in China? Navigating the uncertainties
    Theatre 2 (Rubi)
  119. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  120. Panel discussion
    Theatre 2 (Rubi)
  121. Spotlight
    Theatre 2 (Rubi)
  122. Spotlight
    Theatre 2 (Rubi)
  123. Spotlight: Can the production of iPSC-derived beta islets for Type I diabetes be scaled up to be commercially viable?
    Theatre 2 (Rubi)
  124. Spotlight: From complex to cost-effective: De-risking cell therapy manufacturing with automation and in vivo capabilities
    Theatre 2 (Rubi)
  125. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  126. Spotlight: Do we have clarity on where automation adds real value versus unnecessary cost and complexity?
    Theatre 2 (Rubi)
  127. Spotlight: Can we manufacture in vivo gene therapies at commercial scale?
    Theatre 2 (Rubi)
  128. Spotlight: Flexible, automated platforms for next-generation CGT manufacturing
    Theatre 2 (Rubi)
  129. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  130. Spotlight
    Theatre 2 (Rubi)
  131. Spotlight
    Theatre 2 (Rubi)
  132. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  133. Spotlight: Concept and Case Studies for an enhanced analytical control strategy and practical execution for cell therapies
    Theatre 2 (Rubi)
  134. Spotlight: From cell sourcing to expansion: the role of quality-driven human raw materials in cell therapy
    Theatre 2 (Rubi)
  135. Panel discussion
    Theatre 2 (Rubi)
  136. Spotlight
    Theatre 2 (Rubi)
  137. Spotlight: Accelerating infectivity assay workflows for AAV with automation and AI-assisted data analysis
    Theatre 2 (Rubi)
  138. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  139. Spotlight/Fireside Chat
    Theatre 2 (Rubi)
  140. Panel discussion
    Theatre 2 (Rubi)
  141. Panel discussion
    Theatre 2 (Rubi)
  142. Fireside Chat
    Theatre 2 (Rubi)
  143. Spotlight
    Theatre 2 (Rubi)
  144. Panel discussion
    Theatre 2 (Rubi)
  145. Opening
    Indigo B
  146. Panel: Where is the next wave of investment going?
    Indigo B
  147. Panel: Who funds the fund? The realities of building a biotech investment fund
    Indigo B
  148. Panel: Beyond VC: Alternative funding models for biotech
    Indigo B
  149. Panel: Ask the investors: Your questions, their answers
    Indigo B
  150. Closing
    Indigo B
  151. Opening Panel: From scientist to CEO: The identity shift noone prepares yiu for
    Indigo A
  152. Workshop 1: ARMI | BioFabUSA
    Indigo A
    The Bioindustrial Stack and the capabilities required to advance towards clinical and commercial scale, potentially covering clinical and regulatory readiness, CMC, quality, manufacturing, financing, ...
  153. Workshop 2: C&G development pitfalls
    Indigo A
  154. Workshop 3: Beyond the pitch: What first-time founders don't see comig after the first meeting
    Indigo A
Search